Kirill Osipov commented on the recent invalidation of yet another patent of Russian generic producer Nativa

Pharmaceutical Bulletin – one of the largest professional magazines devoted to Russian pharma – published an article on the recent invalidation of yet another patent of Nativa. Nativa is a Russian generic producer, infamous for its involvement in numerous patent infringement cases with the largest originator makers. Nativa’s patent, rendered invalid in the end of January, was for invention claimed to be dependent on the substance patented by Bristol-Myers Squibb and used in the production of Sprycel.

The Head of Legal Department of ARS-Patent Kirill Osipov provided his comments to Pharmaceutical Bulletin on the case and the acute problem of dependent inventions in general.

The full article is available here.

Make an enquiry